13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
|
Name |
WKN |
Börse |
Kurs |
Datum/Zeit |
Diff. |
Diff. % |
Geld |
Brief |
Erster |
Schluss |
|
SANOFI SA INHABER EO 2 |
920657 |
Xetra |
90,530 |
04.06.24 17:35:32 |
+0,480 |
+0,53% |
0,000 |
0,000 |
90,060 |
90,050 |
|
Regeneron Pharmaceuticals |
881535 |
NASDAQ |
993,290 |
04.06.24 22:00:09 |
+3,810 |
+0,39% |
992,520 |
993,540 |
980,160 |
989,480 |